TANDEM DIABETES CARE, INC. Financials Tandem Diabetes Care, Inc.
Equities
TNDM
US8753722037
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 35.24 USD | -0.90% |
|
+15.81% | +19.13% |
| Apr. 26 | North American Morning Briefing : Tech Still in -2- | DJ |
| Apr. 25 | Leerink Partners Upgrades Tandem Diabetes Care to Outperform Rating, Price Target is $45 | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 3,523 | 5,951 | 9,563 | 2,890 | 1,929 | 2,275 | - | - |
| Enterprise Value (EV) 1 | 3,346 | 6,059 | 9,221 | 2,890 | 1,746 | 2,119 | 2,153 | 2,160 |
| P/E ratio | -142 x | -171 x | 627 x | -30.6 x | -8.62 x | -21.3 x | -34.4 x | -55.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.72 x | 11.9 x | 13.6 x | 3.61 x | 2.58 x | 2.69 x | 2.43 x | 2.23 x |
| EV / Revenue | 9.24 x | 12.1 x | 13.1 x | 3.61 x | 2.34 x | 2.51 x | 2.3 x | 2.11 x |
| EV / EBITDA | -314 x | 2,429 x | 253 x | 54.1 x | -190 x | 1,094 x | 56.8 x | 33 x |
| EV / FCF | 150 x | -2,212 x | 94.9 x | - | -29.8 x | -88.2 x | 71.4 x | 34.5 x |
| FCF Yield | 0.67% | -0.05% | 1.05% | - | -3.36% | -1.13% | 1.4% | 2.9% |
| Price to Book | 17.9 x | 15.9 x | 22.4 x | - | 6.13 x | 7.28 x | 6.84 x | 6.05 x |
| Nbr of stocks (in thousands) | 59,093 | 62,195 | 63,533 | 64,299 | 65,210 | 64,563 | - | - |
| Reference price 2 | 59.61 | 95.68 | 150.5 | 44.95 | 29.58 | 35.24 | 35.24 | 35.24 |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 362.3 | 498.8 | 702.8 | 801.2 | 747.7 | 844.5 | 936.5 | 1,021 |
| EBITDA 1 | -10.65 | 2.494 | 36.5 | 53.41 | -9.191 | 1.937 | 37.88 | 65.39 |
| EBIT 1 | -16.72 | -7.957 | 22.65 | -45.84 | -112.6 | -119.2 | -86.18 | -63.08 |
| Operating Margin | -4.62% | -1.6% | 3.22% | -5.72% | -15.06% | -14.11% | -9.2% | -6.18% |
| Earnings before Tax (EBT) 1 | -24.6 | -36.28 | 15.9 | -92.85 | -220.3 | -112 | -72.61 | -44.93 |
| Net income 1 | -24.75 | -34.38 | 15.57 | -94.59 | -222.6 | -108.6 | -67.71 | -42.24 |
| Net margin | -6.83% | -6.89% | 2.21% | -11.81% | -29.77% | -12.86% | -7.23% | -4.14% |
| EPS 2 | -0.4200 | -0.5600 | 0.2400 | -1.470 | -3.430 | -1.658 | -1.024 | -0.6331 |
| Free Cash Flow 1 | 22.36 | -2.739 | 97.18 | - | -58.61 | -24.02 | 30.16 | 62.54 |
| FCF margin | 6.17% | -0.55% | 13.83% | - | -7.84% | -2.84% | 3.22% | 6.12% |
| FCF Conversion (EBITDA) | - | - | 266.26% | - | - | - | 79.63% | 95.65% |
| FCF Conversion (Net income) | - | - | 624.3% | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 179.6 | 210 | 175.9 | 200.3 | 205.1 | 220.5 | 169.4 | 195.9 | 185.6 | 196.8 | 173.5 | 205 | 218.5 | 248.8 | 199.5 |
| EBITDA 1 | 11.12 | 16.26 | 6.4 | 11.44 | 9.866 | 25.7 | -20.16 | 5.265 | 1.455 | 4.252 | -24.59 | -5.732 | 10.28 | 21.49 | -14.58 |
| EBIT 1 | 7.72 | 12.74 | -15.34 | -12.24 | -15.88 | -2.385 | -127.8 | -38.81 | -23.31 | -22.52 | -52.88 | -35.21 | -21.12 | -9.95 | -40.06 |
| Operating Margin | 4.3% | 6.07% | -8.72% | -6.11% | -7.74% | -1.08% | -75.46% | -19.81% | -12.56% | -11.44% | -30.47% | -17.18% | -9.67% | -4% | -20.08% |
| Earnings before Tax (EBT) 1 | 5.848 | 11.14 | -16.44 | -12.95 | -47.35 | -16.11 | -123.6 | -34.63 | -30.73 | -31.31 | -52.43 | -32.85 | -20.44 | -9.591 | -42.31 |
| Net income 1 | 5.794 | 10.81 | -14.72 | -15.06 | -48.97 | -15.85 | -123.9 | -35.78 | -32.96 | -30 | -50.28 | -33.07 | -19.51 | -7.891 | -32.03 |
| Net margin | 3.23% | 5.15% | -8.37% | -7.52% | -23.87% | -7.19% | -73.13% | -18.26% | -17.76% | -15.25% | -28.98% | -16.14% | -8.93% | -3.17% | -16.05% |
| EPS 2 | 0.0900 | 0.1600 | -0.2300 | -0.2300 | -0.7600 | -0.2500 | -1.920 | -0.5500 | -0.5100 | -0.4600 | -0.7718 | -0.5059 | -0.2959 | -0.1183 | -0.4873 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/3/21 | 2/22/22 | 5/4/22 | 8/3/22 | 11/2/22 | 2/22/23 | 5/3/23 | 8/3/23 | 11/1/23 | 2/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | 108 | - | - | - | - | - | - |
| Net Cash position 1 | 176 | - | 342 | - | 183 | 156 | 122 | 115 |
| Leverage (Debt/EBITDA) | - | 43.45 x | - | - | - | - | - | - |
| Free Cash Flow 1 | 22.4 | -2.74 | 97.2 | - | -58.6 | -24 | 30.2 | 62.5 |
| ROE (net income / shareholders' equity) | -15.2% | -12.3% | 3.89% | -21.7% | -27.1% | -31.4% | -18.2% | -8.33% |
| ROA (Net income/ Total Assets) | -9.3% | -6.6% | 1.92% | -9.66% | -10.2% | -9.05% | -4.6% | -1.7% |
| Assets 1 | 266.2 | 521.3 | 810.8 | 979 | 2,189 | 1,200 | 1,472 | 2,485 |
| Book Value Per Share 2 | 3.330 | 6.010 | 6.730 | - | 4.830 | 4.840 | 5.160 | 5.820 |
| Cash Flow per Share 2 | 0.7200 | 0.4000 | 1.730 | - | -0.4900 | 0.4000 | 1.150 | 1.600 |
| Capex 1 | 19.5 | 27.4 | 14.2 | - | 26.8 | 27.1 | 30 | 36.2 |
| Capex / Sales | 5.39% | 5.49% | 2.02% | - | 3.58% | 3.21% | 3.2% | 3.54% |
| Announcement Date | 2/24/20 | 2/24/21 | 2/22/22 | 2/22/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
35.24
USD
Average target price
35.64
USD
Spread / Average Target
+1.14%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +19.13% | 2.28B | |
| -2.31% | 187B | |
| -3.20% | 106B | |
| -5.04% | 66.9B | |
| +0.20% | 49.45B | |
| +17.29% | 48B | |
| +4.06% | 40.84B | |
| +2.36% | 26.25B | |
| +2.07% | 26.48B | |
| +12.96% | 24.62B |
- Stock Market
- Equities
- TNDM Stock
- Financials Tandem Diabetes Care, Inc.
